Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Times Interest Earned (2020 - 2025)

Barinthus Biotherapeutics' Times Interest Earned history spans 6 years, with the latest figure at -$889.62 for Q4 2025.

  • For Q4 2025, Times Interest Earned rose 54.36% year-over-year to -$889.62; the TTM value through Dec 2025 reached -$1383.4, down 7.87%, while the annual FY2025 figure was -$1383.4, 7.87% down from the prior year.
  • Times Interest Earned reached -$889.62 in Q4 2025 per BRNS's latest filing, up from -$1158.9 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $8.84 in Q1 2022 to a low of -$2855.4 in Q4 2023.
  • Average Times Interest Earned over 5 years is -$1354.9, with a median of -$1466.7 recorded in 2024.
  • Peak YoY movement for Times Interest Earned: tumbled 25191.25% in 2021, then surged 479.46% in 2022.
  • A 5-year view of Times Interest Earned shows it stood at -$926.0 in 2021, then soared by 100.95% to $8.84 in 2022, then crashed by 32409.13% to -$2855.4 in 2023, then skyrocketed by 31.74% to -$1949.2 in 2024, then soared by 54.36% to -$889.62 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Times Interest Earned are -$889.62 (Q4 2025), -$1158.9 (Q3 2025), and -$1943.7 (Q2 2025).